The Value of Progression-Free Survival

4:15 PM - 5:15 PM, Wednesday, June 5,2019 ・ 105AB, Level 100
Clinical trials are designed to measure for multiple endpoints including overall survival (OS), progression-free survival (PFS), event-free survival, or response rate. However, health systems continue to prioritize OS over other relevant endpoints, and increasingly value frameworks such as the ESMO magnitude of clinical benefit scale and ASCO’s Value Framework attach higher value to OS as well. While OS will also continue to be the “gold standards” of endpoints, this approach has implications for patients, as well for manufactures as it affects clinical trial times. Also, this is a divergent approach from regulators, who are working to broaden their consideration of endpoints to promote breakthrough therapies at earlier access. This panel will discuss the necessity and relevance of PFS and other endpoints in clinical studies and patient care, as well as the relevant needs of different systems given no methodological standard exists.
Speakers
photo
Director, Division of Oncology Products 2
Center for Drug Evaluation and Research (CDER), FDA
photo
Chief Medical Officer
Seattle Genetics
photo
Senior Vice President, Education and Support Programs
Cancer Support Community
photo
Executive Vice President, Chief Medical Officer
Incyte